

## **Prof. Dr. Dr. H. Hefter: Auswahl von 40 Veröffentlichungen (2019-2022)**

1. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy  
Philipp Albrecht, Alexander Jansen, John-Ih Lee, Marek Moll, Marius Ringelstein, Dietmar Rosenthal, Hans Bigalke, Orhan Aktas, Hans-Peter Hartung, **Harald Hefter** - *Neurology*, 2019
2. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature  
Sara Samadzadeh, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, John-Ih Lee, Philipp Albrecht, **Harald Hefter**; *Toxins* 2020, 12(8), 499; <https://doi.org/10.3390/toxins12080499>
3. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study  
**Harald Hefter**, Raphaela Brauns, Beyza Ürer, Dietmar Rosenthal, Philipp Albrecht; *Journal of Neurology* 2020; **volume 267**, pages 1340–1347
4. Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review  
**Harald Hefter**, Sara Samadzadeh; *Toxins* 2021, 13(4), 241; <https://doi.org/10.3390/toxins13040241>
5. Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins  
**Harald Hefter\***, Christian J. Hartmann, Ulrike Kahlen, Sara Samadzadeh, Dietmar Rosenthal; Marek Moll; *Front. Neurol.* 2021 | <https://doi.org/10.3389/fneur.2021.636590>
6. Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop  
**Harald Hefter**, Werner Nickels, Dietmar Rosenthal, Sara Samadzadeh, Philipp Albrecht; *Toxins* 2021, 13(7), 466; <https://doi.org/10.3390/toxins13070466>
7. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia  
**Harald Hefter**, Dietmar Rosenthal, Hans Bigalke, Marek Moll  
*Ther Adv. 2019*, <https://doi.org/10.1177/1756286419892078>

8. Long-term adherence and response to botulinum toxin in different indications  
John-Ih Lee, Alexander Jansen, Sara Samadzadeh, Ulrike Kahlen, Marek Moll, Marius Ringelstein, Giulia Soncin, Hans Bigalke, Orhan Aktas, Alexia-Sabine Moldovan, Julia Waskoenig, Sebastian Jander, Michael Gliem, Alfons Schnitzler, Hans-Peter Hartung, **Harald Hefter**, Philipp Albrecht  
*Ann Clin Transl Neurol* 2021; <https://doi.org/10.1002/acn3.51225>
9. Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson's Disease  
Sara Samadzadeh, **Harald Hefter**, Osman Tezayak, Dietmar Rosenthal  
*J. Funct. Morphol. Kinesiol.* 2022, 7(1), 5; <https://doi.org/10.3390/jfmk7010005>
10. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA  
**Harald Hefter**, Sara Samadzadeh, Marek Moll  
*Toxins* 2020, 12(11), 677; <https://doi.org/10.3390/toxins12110677>
11. The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany  
Sara Samadzadeh, Raphaela Brauns, Dietmar Rosenthal, **Harald Hefter**  
*Toxins* 2021, 13(2), 101; <https://doi.org/10.3390/toxins13020101>